NYSE:ABBVAbbVie Stock Price, Forecast & News

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABBV shares have increased by 17.0% and is now trading at $99.28. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AbbVie.

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 31st 2020. View our earnings forecast for AbbVie.

AbbVie will be holding an earnings conference call on Friday, July 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AbbVie Inc (NYSE:ABBV) posted its quarterly earnings results on Friday, May, 1st. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.25 by $0.17. The business earned $8.62 billion during the quarter, compared to the consensus estimate of $8.31 billion. AbbVie had a net margin of 24.77% and a negative return on equity of 169.80%. The company's quarterly revenue was up 10.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.14 earnings per share. View AbbVie's earnings history.

AbbVie declared a quarterly dividend on Wednesday, June 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.18 per share on Friday, August 14th. This represents a $4.72 dividend on an annualized basis and a dividend yield of 4.75%. The ex-dividend date is Tuesday, July 14th. View AbbVie's dividend history.

AbbVie declared that its Board of Directors has approved a stock repurchase program on Thursday, December 13th 2018, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy up to 3.8% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's management believes its shares are undervalued.

AbbVie issued an update on its FY 2020 After-Hours earnings guidance on Friday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $50-50 billion.

17 brokerages have issued twelve-month price targets for AbbVie's stock. Their forecasts range from $90.00 to $125.00. On average, they expect AbbVie's stock price to reach $106.80 in the next year. This suggests a possible upside of 7.6% from the stock's current price. View analysts' price targets for AbbVie.

Media stories about ABBV stock have trended negative this week, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AbbVie earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Bristol-Myers Squibb (BMY) and Valeant Pharmaceuticals Intl (VRX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by many different retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.15%), DNB Asset Management AS (0.07%), State of Alaska Department of Revenue (0.02%), Park National Corp OH (0.01%), Thomasville National Bank (0.01%) and Woodstock Corp (0.01%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, HNP Capital LLC, Park National Corp OH, First National Bank of Mount Dora Trust Investment Services, Birch Capital Management LLC, Fulton Bank N. A., M&R Capital Management Inc., and Foundation Resource Management Inc.. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Jeffrey Ryan Stewart, and Timothy J Richmond. View insider buying and selling activity for AbbVie.

ABBV stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Envestnet Asset Management Inc., State of Alaska Department of Revenue, Mountain Capital Investment Advisors Inc, Livforsakringsbolaget Skandia Omsesidigt, Silverleafe Capital Partners LLC, Woodstock Corp, and Trinity Legacy Partners LLC. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $99.28.

AbbVie has a market capitalization of $146.61 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

The official website for AbbVie is www.abbvie.com.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.